Charles River Laboratories International (CRL) Earnings Analysis
Charles River Laboratories International (CRL) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS 2.06 USD vs 1.96 USD est (+5.1%). It has beaten estimates in 3/3 recent quarters (100%). Trailing P/E -58.32.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CRL next report earnings?
No confirmed upcoming earnings date is currently scheduled for CRL. This page updates as the calendar is published.
CRL earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 2.06 USD | 1.96 USD | +5.1% | Beat |
| 2026-02-18 | 2.39 USD | 2.33 USD | +2.6% | Beat |
| 2025-02-19 | 2.66 USD | 2.5 USD | +6.4% | Beat |
Beat rate: 3/3 (100%) over reported quarters with consensus data.
CRL valuation and analyst view
| Trailing P/E | -58.32 |
|---|---|
| Trailing EPS | -3.77214 USD |
| Price / book | 3.64 |
| Dividend yield | 0.00% |
| Market cap | 10.63B |
| Analyst consensus | Buy (26 buy / 11 hold / 0 sell) |
| Avg price target | 227.4 USD |
Related research pages
Frequently asked questions
When is Charles River Laboratories International (CRL)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for CRL. This page updates as the calendar is published.
Did CRL beat earnings last quarter?
In its 2026-05-07 report, CRL posted EPS of 2.06 USD versus a 1.96 USD estimate — a beat of 5.1%.
What is CRL's earnings track record?
Over the last 3 reported quarters with consensus data, CRL beat estimates 3 times (100%).
What is CRL's current P/E ratio and EPS?
CRL trades at a trailing P/E of -58.32 on trailing EPS of -3.7721394864252007 USD.
What do analysts rate CRL?
Analyst consensus is "Buy" across 37 ratings (1 strong buy, 25 buy, 11 hold, 0 sell, 0 strong sell). Average 12-month price target: 227.4 USD.